200 related articles for article (PubMed ID: 31831337)
21. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
[TBL] [Abstract][Full Text] [Related]
22. Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis.
Sharma N; Evans TA; Pellicore MJ; Davis E; Aksit MA; McCague AF; Joynt AT; Lu Z; Han ST; Anzmann AF; Lam AN; Thaxton A; West N; Merlo C; Gottschalk LB; Raraigh KS; Sosnay PR; Cotton CU; Cutting GR
PLoS Genet; 2018 Nov; 14(11):e1007723. PubMed ID: 30444886
[TBL] [Abstract][Full Text] [Related]
23. Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells.
Li C; Liu Z; Anderson J; Liu Z; Tang L; Li Y; Peng N; Chen J; Liu X; Fu L; Townes TM; Rowe SM; Bedwell DM; Guimbellot J; Zhao R
PLoS One; 2023; 18(11):e0295009. PubMed ID: 38019847
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators.
Laselva O; McCormack J; Bartlett C; Ip W; Gunawardena TNA; Ouyang H; Eckford PDW; Gonska T; Moraes TJ; Bear CE
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33167369
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough.
Lee RE; Lewis CA; He L; Bulik-Sullivan EC; Gallant SC; Mascenik TM; Dang H; Cholon DM; Gentzsch M; Morton LC; Minges JT; Theile JW; Castle NA; Knowles MR; Kimple AJ; Randell SH
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35900863
[TBL] [Abstract][Full Text] [Related]
26. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.
Clarke LA; Awatade NT; Felício VM; Silva IA; Calucho M; Pereira L; Azevedo P; Cavaco J; Barreto C; Bertuzzo C; Gartner S; Beekman J; Amaral MD
Hum Mutat; 2019 Mar; 40(3):326-334. PubMed ID: 30488522
[TBL] [Abstract][Full Text] [Related]
27. Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis.
Clarke LA; Luz VCC; Targowski S; Ramalho SS; Farinha CM; Amaral MD
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828417
[TBL] [Abstract][Full Text] [Related]
28. Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells.
Valley HC; Bukis KM; Bell A; Cheng Y; Wong E; Jordan NJ; Allaire NE; Sivachenko A; Liang F; Bihler H; Thomas PJ; Mahiou J; Mense M
J Cyst Fibros; 2019 Jul; 18(4):476-483. PubMed ID: 30563749
[TBL] [Abstract][Full Text] [Related]
29. Nonsense-mediated mRNA decay and cystic fibrosis.
Linde L; Kerem B
Methods Mol Biol; 2011; 741():137-54. PubMed ID: 21594783
[TBL] [Abstract][Full Text] [Related]
30. Rescue of nonsense mutations by amlexanox in human cells.
Gonzalez-Hilarion S; Beghyn T; Jia J; Debreuck N; Berte G; Mamchaoui K; Mouly V; Gruenert DC; Déprez B; Lejeune F
Orphanet J Rare Dis; 2012 Aug; 7():58. PubMed ID: 22938201
[TBL] [Abstract][Full Text] [Related]
31. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
[TBL] [Abstract][Full Text] [Related]
32. Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis.
Gunawardena TNA; Bozóky Z; Bartlett C; Ouyang H; Eckford PDW; Moraes TJ; Ratjen F; Gonska T; Bear CE
Cells; 2023 Apr; 12(8):. PubMed ID: 37190083
[TBL] [Abstract][Full Text] [Related]
33. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator.
Luciani A; Villella VR; Esposito S; Gavina M; Russo I; Silano M; Guido S; Pettoello-Mantovani M; Carnuccio R; Scholte B; De Matteis A; Maiuri MC; Raia V; Luini A; Kroemer G; Maiuri L
Autophagy; 2012 Nov; 8(11):1657-72. PubMed ID: 22874563
[TBL] [Abstract][Full Text] [Related]
34. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
35. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
36. Investigating REPAIRv2 as a Tool to Edit
Melfi R; Cancemi P; Chiavetta R; Barra V; Lentini L; Di Leonardo A
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640650
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
38. Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.
Xue X; Mutyam V; Thakerar A; Mobley J; Bridges RJ; Rowe SM; Keeling KM; Bedwell DM
Hum Mol Genet; 2017 Aug; 26(16):3116-3129. PubMed ID: 28575328
[TBL] [Abstract][Full Text] [Related]
39. Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems.
Pibiri I; Melfi R; Tutone M; Di Leonardo A; Pace A; Lentini L
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899265
[TBL] [Abstract][Full Text] [Related]
40. Site-Specific RNA Editing of Stop Mutations in the CFTR mRNA of Human Bronchial Cultured Cells.
Chiavetta RF; Titoli S; Barra V; Cancemi P; Melfi R; Di Leonardo A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
